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Background and Purpose: Majority of patients with locoregionally recurrent rectal
cancer will require re-irradation (reRT). This study aimed to analyze the treatment
outcomes, particularly infield progression, and severe late toxicity rates after reRT for
recurrent rectal cancer and further identify a subgroup of patients who may optimally
benefit from reRT.
Materials and Methods: Patients with rectal cancer who underwent reRT to the pelvis
between January 2000 and December 2017 were included for analysis.
Results: The records of 41 patients were retrospectively reviewed. The median
follow-up period after reRT was 53.7 months (range 3.5–130.3 months). The 2-year
infield progression-free rate (IPFR) was 49.4%. The 2-year overall survival (OS) and
progression-free survival (PFS) rates were 55.3 and 28.5%, respectively. Severe late
toxicity events occurred in 17 patients, and the median time from reRT to severe late
toxicity event was 10.5 months (range 2.3–33.3 months). The 2-year severe late toxicity
free-rate (SLTFR) was 55.5%, and the median SLTFR was 33.3 months. Patients who
did not experience severe late toxicity events showed a significantly higher number of
recurred tumors at the posterior or lateral location compared to axial or anterior location.
The selected subgroup with recurrent tumor size <3.3 cm and treated with total reRT
dose of >50 Gyab10 (n = 13) showed superior IPFR, OS, and PFS to the other patients.
Conclusion: ReRT was a reasonable treatment option for patients with locoregionally
recurrent rectal cancer. However, severe late toxicity rates were substantially high. Thus,
patients indicated for ReRT with curative dose should be selected properly according to
tumor size and location.
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INTRODUCTION
Rectal cancer is among the most common malignancies, with
∼39,910 new cases in the United States in 2017 (1). Treatment
outcomes for rectal cancer have considerably improved in
recent years owing to advances in multidisciplinary treatments
including surgery, radiotherapy (RT), and chemotherapy.
Particularly, neoadjuvant concurrent chemoradiotherapy
(CCRT) and total mesorectal excision have contributed to a
decreased rate of local recurrences (2–4). However, despite
advances in treatment modalities, local recurrences still occur in
5–15% of patients, and the majority of locoregional recurrences
occur within the initial RT field (5, 6). Recurrences within the
pelvis are associated with increased morbidity and mortality,
and surgery is the first treatment option in these cases (6, 7).
However, some patients are ineligible for surgery due to poor
general condition or tumor extent and location (8). In these
cases, RT can help in achieving R0 resection, improving local
control, or palliating the symptoms (7), and re-irradation (reRT)
will be necessary in the majority of these patients since most
recurrences will be within the initial RT field (5).
Several factors have to be considered in planning reRT,
including disease extent, organs at risk (OARs), dose
fractionation, interval from previous RT, prognosis, and general
condition. However, retrospective and prospective studies on
reRT are limited, and the treatment schemes, median survival,
and toxicity rates vary in these studies (7, 9–14). Many studies
have reported the feasibility of reRT for locoregional recurrences,
including preoperative RT, definitive RT, and intraoperative RT
(15–19). We have previously reported the treatment outcomes
and toxicity rates of patients with recurrent rectal cancer who
underwent reRT in our institution (20). However, because the
study included only a small number of patients and the follow-up
period was short, we wanted to perform a retrospective review
with more patients and longer follow-up. In this study, we
aimed to analyze the treatment outcomes, particularly infield
progression, and severe late toxicity after reRT for recurrent
rectal cancer and further identify a subgroup of patients who
may optimally benefit from reRT without increased severe
late toxicity.
MATERIALS AND METHODS
Patient Selection
We retrospectively reviewed the medical records of patients with
rectal cancer who underwent reRT to the pelvis from January
2000 to December 2017. Patients who underwent surgery and
preoperative or postoperative RT with or without chemotherapy
as initial curative treatment were included, while those who did
not receive RT as part of initial treatment and those who did not
receive reRT to the pelvis were excluded. The study was approved
Abbreviations: CCRT, concurrent chemoradiotherapy; CI, confidence interval;
CTCAE, Common Terminology Criteria for Adverse Events; GTV, gross tumor
volume; HR, hazard ratio; IMRT, intensity-modulated radiotherapy; IPFR, infield
progression-free rate; OPFR, outfield progression-free rate; OARs, organs at risk;
OS, overall survival; PFS, progression-free survival; PTV, planning target volume;
reRT, re-irradation, RT, radiotherapy; SLTFR, severe late toxicity free-rate.
by the Institutional Review Board of Severance hospital (IRB
no. 4-2019-0344).
Re-Irradiation
A multidisciplinary team determined whether patients should
receive reRT. All patients’ imaging studies were reviewed and
were clinically diagnosed as rectal cancer recurrences. Thus,
pathologic diagnosis was not mandatory. The planning target
volume was the recurred gross tumor volume plus 0.5–3 cm
margin depending on the physician’s preference. In most cases,
margins were 0.5–1 cm and were reduced when OARs were close.
When planning, dose-constraints for OARs were prioritized
compared to target volumes in majority of cases. Median reRT
dose was 50Gy (range 30–60Gy) with a fractional dose of
median 2Gy (range 1.2–6.0Gy). Thirty-eight patients received
reRT by conventional fractionation, two patients received reRT
by hypofractionated regimen, and one patient received BID
treatment. In our institution, tomotherapy was first introduced
in 2006; since then, the number of patients receiving reRT
via intensity-modulated radiotherapy (IMRT) increased. Prior
to 2010, more than half of the patients (61.9%) received reRT
via 3D conformal radiotherapy (3DCRT), but since 2010, 90%
of the patients received reRT via IMRT. Hypofractionated
reRT with fractional doses of 5 or 6Gy was performed via
cyberknife and conventional fractionation reRT was performed
via IMRT.
As for chemotherapy, twenty-one patients
received concurrent chemotherapy during reRT with
regimens such as xeloda, 5-fluorouracil/leucovorin
and 5-fluorouracil/leucovorin/oxaliplatin.
Response and Toxicity Assessment and
Follow-Up
Treatment response was evaluated according to the Response
Evaluation Criteria in Solid Tumors. Follow-up evaluation
was performed at 1 and 3 months after reRT and routinely
thereafter. Acute and late toxicity events were thoroughly
reviewed retrospectively and graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE) version 4.03. Severe toxicity events were
defined as toxicity events of grade 3 or higher. The primary
endpoints were severe late toxicity-free rate (SLTFR) and
infield progression-free rate (IPFR). Infield progression was
defined as recurrence or disease progression within the
re-irradiation field. The secondary endpoints were overall
survival (OS), progression-free survival (PFS), and outfield
progression-free rate (OPFR). Outfield progression was defined
as recurrence or progression of the disease outside the re-
irradiation field.
Statistical Analysis
The cumulative probabilities of SLTFR, IPFR, OS, PFS, and
OPFR were calculated using the Kaplan-Meier method and
compared using log-rank test for subgroup analysis. The SLTFR,
IPFR, OS, PFS, and OPFR were defined as the time from
reRT until the corresponding event or the date of last follow-
up in our institution. Univariate and multivariate analyses
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TABLE 1 | Patient and tumor characteristics at recurrence.
n %
CEA (ng/mL)
Median (range) 6.82 (0.20–109.28)
Histology
Adenocarcinoma 14 34.1
Mucinous ca 1 2.4
Not confirmed 26 63.4
Pattern of failure
Local only 24 58.5
Regional only 6 14.6
Locoregional 6 14.6
Local & distant 2 4.9
Regional & distant 1 2.4
Local, regional & distant 2 4.9
Tumor size (cm)
Median (range) 3.3 (1.5–11.0)
<3.3 cm 20 48.8
≥3.3 cm 21 51.2
Initial RT isodose line
< 40Gy 3 7.3
40–45Gy 7 17.1
45–50Gy 5 12.2
≥ 50Gy 26 63.4
Guillem class
Axial 10 24.4
Anterior 8 19.5
Posterior 9 22
Lateral 8 19.5
Anterior & lateral 5 12.2
Posterior & lateral 1 2.4
rT stage
T0 6 14.6
T1 0 0
T2 0 0
T3 7 17.1
T4 28 68.3
rN stage
N0 29 70.7
N1 10 24.4
N2 2 4.9
R-stage
II 26 63.4
III 10 24.4
IV 5 12.2
CEA, carcinoembryonic antigen; RT, radiotherapy.
were performed using Cox’s regression. A backward elimination
method including all the variables was used for multivariate
analyses. Clinical factors associated with severe late toxicity and
infield progression were analyzed using the χ2 and Fisher’s exact
tests. All analyses were performed using the SPSS version 23.0
(IBM Inc., Armonk, NY, USA).
TABLE 2 | Treatment characteristics at recurrence.
n %
RT modality
3DCRT 15 36.6
IMRT/Cyberknife 26 63.4
Re-RT total dose (Gy)
Median (range) 50 (30.0–60.0)
Re-RT dose per fraction (Gy)
Median (range) 2 (1.2–6.0)
Re-RT total dose in EQD2 (Gyab10)
Median (range) 50.82 (28.00–65.00)
Re-RT total dose in EQD2 (Gyab3)
Median (range) 51.84 (25.20–86.40)
Sum total dose (Gy)
Median (range) 104 (43.2–119.4)
Sum total dose in EQD2 (Gyab10)
Median (range) 105.18 (42.48–123.41)
Sum total dose in EQD2 (Gyab3)
Median (range) 105.84 (41.47–134.78)
Re-RT duration (days)
Median (range) 36 (13–69)
Re-RT completion of planned dose
No 1 2.4
Yes 40 97.6
Rest during re-RT
No 36 87.8
Yes 5 12.2
Concurrent chemotherapy
No 20 48.8
Yes 21 51.2
RT, radiotherapy; 3DCRT, 3D conformal radiotherapy; IMRT, intensity-
modulated radiotherapy.
RESULTS
Patient, Tumor, and Treatment
Characteristics at Initial Diagnosis and
at Recurrence
A total of 41 patients were included for analysis. The patient,
tumor, and treatment characteristics at the time of initial
diagnosis are shown in Supplementary Tables 1, 2. The majority
of patients were male, and the median age was 55 years. More
than 50% of the patients were diagnosed with low rectal cancer
with definitive or borderline circumferential resection margin
threatening. Half of the patients received preoperative CCRT,
while the other half received postoperative RT, and most patients
received adjuvant chemotherapy. All except two patients received
3DCRT, with a median dose of 50.4Gy (range 45–60 Gy).
The patient, tumor, and treatment characteristics including
patterns of failure at the time of recurrence prior to reRT
are shown in Tables 1, 2. More than half of the recurrences
were local only, and around 90% were local and/or regional
recurrences. The median size of the recurred tumor was
3.3 cm. The majority (63.4%) of recurrences were infield
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TABLE 3 | Acute and late toxicities.
Severity n (%)
Adverse event None n (%) G1 G2 G3 G4
Acute toxicity
Diarrhea 33 (80.5%) 3 (7.3%) 2 (4.9%) 3 (7.3%) 0 (0.0%)
Proctitis 33 (80.5%) 5 (12.2%) 3 (7.3%) 0 (0.0%) 0 (0.0%)
Cystitis 34 (82.9%) 4 (9.8%) 3 (7.3%) 0 (0.0%) 0 (0.0%)
Late toxicity
Fistula 27 (65.9%) 3 (7.3%) 3 (7.3%) 7 (17.1%) 1 (2.4%)
Bowel obstruction 31 (75.6%) 1 (2.4%) 0 (0.0%) 7 (17.1%) 2 (4.9%)
GU toxicity 36 (87.8%) 0 (0.0%) 1 (2.4%) 4 (9.8%) 0 (0.0%)
None n (%) Yes n (%)
Abscess 30 (73.2%) 11 (26.8%)
G, grade; GU, genitourinary.
FIGURE 1 | Kaplan-Meier estimates of infield progression-free rate (A) and severe late toxicity-free rate (B) according to groups divided by treatment aim (Group 1,
salvage reRT with a surgical component; Group 2, definitive reRT; Group 3, palliative reRT).
recurrences within the ≥50Gy isodose line. The location
of the recurred tumor was classified using the Guillem
classification criteria as follows: (1) axial: not involving the
anterior, posterior, or lateral pelvic walls—including anastomotic
recurrence after low anterior resection, local recurrence after
transanal or transsphincteric excision, and perineal recurrence
after abdomino-perineal resection; (2) anterior: involving the
urinary bladder, vagina, uterus, seminal vesicles, or prostate;
(3) posterior: involving the sacrum and coccyx; and (4)
lateral: involving the bony pelvic sidewall or sidewall structures
including the iliac vessels, pelvic ureters, lateral lymph nodes,
pelvic autonomic nerves, and sidewall musculature. The numbers
of recurred tumors were similar for each classification. ReRT
was performed via IMRT or CyberKnife in 26 patients.
Because few patients received hypofractionated RT, the range
of total dose and dose per fraction for reRT varied widely.
The median reRT dose was 50Gy (range 30–60Gy), with a
median fractional dose of 2Gy (range 1.2–6.0Gy). The median
follow-up period after reRT was 53.7 months (range 3.5–
130.3 months).
For equal comparison, the total reRT dose and the sum
of previous RT and reRT dose were calculated as EQD2 with
an a/b value of 3 for normal tissue and 10 for tumors. All
but one patient, who did not come on his own will for the
last treatment session, completed the planned dose. A total of
5 patients had to rest during reRT; 1 patient did not come
on his own will, 2 patients due to chemotherapy, 1 patient
due to septic shock from urinary tract infection, and 1 due to
perineal soreness. Thus, only 1 patient had to rest during reRT
because of acute toxicity. The reason for the rest in patients who
had chemotherapy was because their insurance policies did not
allow chemotherapy and radiotherapy to be conducted on the
same day.
Clinical Outcomes and Toxicity
After Re-Irradiation
Tumor response after reRT is shown in Supplementary Table 3.
One month after reRT, 5 of the 41 cases (12.5%) showed
progressive disease, and at 3 months, 3 cases (9.1%) showed
progressive disease. A total of 9 patients underwent surgery after
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TABLE 4 | Late toxicity for groups according to treatment aim.
Severity n (%)
Adverse event Group 1 Group 2 Group 3
Late toxicity
Fistula
Grade 0 5 (18.5%) 16 (59.3%) 6 (22.2%)
Grade 1–2 1 (16.7%) 3 (50.0%) 2 (33.3%)
Grade 3–4 2 (25.0%) 4 (50.0%) 2 (25.0%)
Bowel obstruction
Grade 0 7 (22.6%) 16 (51.6%) 8 (25.8%)
Grade 1–2 0 (0.0%) 1 (100.0%) 0 (0.0%)
Grade 3–4 1 (11.1%) 6 (66.7%) 2 (22.2%)
GU toxicity
Grade 0 8 (22.2%) 19 (52.8%) 9 (25.0%)
Grade 1–2 0 (0.0%) 0 (0.0%) 1 (100.0%)
Grade 3–4 0 (0.0%) 4 (100.0%) 0 (0.0%)
Group 1 Group 2 Group 3
Abscess
No 3 (10.0%) 20 (66.7%) 7 (23.3%)
Yes 5 (45.5%) 3 (27.3%) 3 (27.3%)
G, grade; GU, genitourinary.
reRT. Of these, 5 patients underwent surgery due to progressive
disease, while the other 4 patients underwent salvage surgery after
showing stable or partial response. The pathology results showed
to be Mandard grade 1, 2, or 3.
The 2-year IPFR was 49.4%, and the median IPFR was
23.3 months. Meanwhile, the 2-year OPFR was 47.9%, and
the median was 22.9 months. The 2-year OS and PFS rates
were 55.3 and 28.5%, respectively, and the median OS and
PFS were 33.8 months and 12.8 months, respectively. Patients
with recurred tumors smaller than 3.3cm showed better results
for all IPFR (p = 0.006, Supplementary Figure 1A), OS (p
< 0.001, Supplementary Figure 1B) and PFS (p = 0.020,
Supplementary Figure 1C). Also, patients with tumors treated
with reRT doses larger than EQD2 50 Gyab10 showed better
results for all IPFR (p < 0.001, Supplementary Figure 2A), OS
(p = 0.002, Supplementary Figure 2B) and PFS (p = 0.001,
Supplementary Figure 2C).
Acute and late toxicity events are shown in Table 3. For acute
toxicity, 3 patients experienced grade 3 diarrhea, but there were
no grade 4 or higher toxicity events. Also, no patient experienced
any proctitis or cystitis as severe acute toxicity events. As for late
toxicity, severe late toxicity events occurred in 17 patients, and
the median time from re-irradiation to the development of severe
late toxicity event was 10.5 months (range 2.3–33.3 months). A
total of 8 severe fistula events (19.5%), 9 bowel obstruction events
(22.0%), and 4 genitourinary toxicity events (9.8%) including
ureteral or urethral stricture and hematuria occurred. Because
abscess is not included in the CTCAE, abscess cases were not
graded, but it was seen in 11 patients.
Comparison of the tumor and treatment characteristics at
recurrence between those who did and did not experience
severe late toxicity events showed that the tumor location
was significantly different between the two groups, with a
higher number of recurred tumors at the posterior or lateral
location in those who did not experience severe late toxicity
events (Supplementary Table 4). The median SLTFR was 33.3
months, and the 2-year SLTFR was 55.5%.
Evaluation of Severe Late Toxicity Cases:
Relationship Between the Area of Severe
Late Toxicity Event and the Target Volume
ReRT plans and imaging studies at the time of severe late toxicity
event were reviewed. In 3 patients, evaluation via imaging studies
was not possible because the area of severe late toxicity was not
clear by imaging studies. In 7 patients, reRT was performed at
the gross tumor volume (GTV) with a minimal margin, and close
OARs were considered when planning. In the other 7 patients,
as shown in an example in Supplementary Figure 3, the related
area of severe toxicity of the OAR was included in the PTV, and
not the GTV.
Analysis of Groups Divided by
Treatment Aim
For additional analysis, patients were divided into three groups
depending on treatment aim: group 1, salvage reRT with a
surgical component (n = 8); group 2, definitive reRT (n = 23);
group 3, palliative reRT (n = 10). Median recurred tumor size
was 3.4, 2.9 and 6.0 cm for group 1, 2 and 3, respectively. Median
reRT total dose was 50.0, 50.4 and 45.0Gy and median reRT dose
in EQD2 was 49.8, 53.1 and 47.1 Gyab10 respectively, for group 1,
2, and 3.
Median infield progression-free period was 16.5, 31.8 and 12.8
months for group 1, 2 and 3, respectively, with group 2 showing
significantly better IPFR compared to the other two groups (p =
0.003, Figure 1A). The OPFR showed no significant difference
between the three groups (p= 0.243). Median OS was 33.9, 47.3,
and 14.9 months for group 1, 2, and 3, respectively, with group
3 showing significantly inferior OS compared to the other two
groups (p = 0.002, Supplementary Figure 4A). As for PFS, the
median period was 10.5, 17.3, and 2.8 months, respectively, for
group 1, 2, and 3, with group 3 showing significantly worse PFS
compared to group 2 (p= 0.005, Supplementary Figure 4B).
As for toxicity, although SLTFR were not significantly
different between the three groups (p = 0.852, Figure 1B),
majority of patients who experienced severe late toxicity were
in group 2 as shown in Table 4. As for those who experienced
abscess, half of the patients were in group 1.
Subgroup Analysis Based on Severe Late
Toxicity and Infield Progression
Given that severe late toxicity events occurred in 17 patients
(41.5%), a subgroup analysis was performed to investigate if
there would be a group in which infield progression could
be minimized with lower severe late toxicity. Considering the
significant factors for IPFR, a subgroup of patients with recurred
tumor size <3.3 cm and those treated with a total reRT dose
of >50 Gyab10 (n = 13) was compared with the rest of the
patients. The selected subgroup showed superior IPFR (p =
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FIGURE 2 | Kaplan-Meier estimates of infield progression-free rate (A), and severe late toxicity-free rate (B) according to the selected patient subgroup or other
patients.
0.002, Figure 2A), OS (p< 0.001), and PFS (p= 0.002) compared
to the other patients. For SLTFR (Figure 2B), the 2-year rates
were higher in the subgroup than that in the other patients (76.2
vs. 42.2%), but the difference was not statistically significant.
DISCUSSION
Despite the advances in treatment modalities in rectal cancer,
local recurrence remains a treatment challenge for all clinicians.
Although surgery is the first treatment option for patients with
local recurrence, there are many cases in which reRT is needed to
increase the probability of R0 resection or for inoperable cases. In
our study, a total of 41 patients who received reRT to the pelvis
for locoregionally recurrent rectal cancer were analyzed. The 2-
year IPFR and SLTFR were 49.4 and 55.5%, respectively, with a
median period of 23.3 and 33.3 months, respectively. A subgroup
analysis of patients with recurred tumor size <3.3 cm and those
treated with a total reRT dose of >50 Gyab10 showed that these
factors may be used to select patients who will benefit optimally
from reRT.
In our study, the median OS of 33.8 months for those who
did not underwent surgery after reRT were superior compared
to that in previous studies, while the median OS of 27.7 months
for those who underwent surgery was inferior to that in other
reports (10, 12, 13, 21). This is probably because 5 of the 9
patients who underwent surgery showed progressive disease at
time of the surgery. Recently, Guren et al. reviewed the results
of 10 previous studies (4 prospective studies and 6 retrospective
reports) and reported a median total dose of 30 to 40Gy to the
GTV with a 1–4 cm margin and a median survival of 39–60
months and 12–16 months in patients who underwent resection
and palliation, respectively, (9). Many studies reported favorable
outcomes in patients treated with reRT with a salvage intent, not
palliative intent (10, 12, 14, 22). In conjunction with previous
studies, our additional analysis performed with groups divided by
treatment aim showed the worst results for OS and PFS in group
3 (palliative reRT group).
As for acute toxicity, the rate ranged from 9 to 20% in previous
studies (7, 9–14). Similarly, our study showed 3 cases of acute
toxicity (7.3%), and almost all patients completed reRT without
any treatment break, indicating that reRT treatment itself is
tolerable. However, severe late toxicity events occurred in 17
patients (41.5%). Previously, late toxicity has been insufficiently
reported, and the rate of severe late toxicity varied widely (7, 9–
14, 23). In our study, we observed 7 cases of severe toxicity in
which the related area of theOARwas included in the PTV. Using
modern techniques such as IMRT to target only the GTV and
further reducing the dose to nearby OARs may help reduce the
severe late toxicity events. Additional analysis for groups divided
by treatment aim showed that the majority of patients who
experienced severe late toxicity were in group 2 (definitive reRT
group). Group 2 may have shown the highest severe late toxicity
rate since patients in group 1 may have received surgery before
severe late toxicity events occurred near the recurred tumor area.
Also, since group 3 showed the shortest median OS period of 14.9
months, some patients in group 3 may have expired before the
occurrence of late toxicity events.
We wanted to identify a subgroup that could achieve high
local control with low severe late toxicity rates. A subgroup of
patients with recurred tumor size<3.3 cm and treated with a total
reRT dose of >50 Gyab10 was compared with the other patients.
Although the differences were not statistically significant for
SLTFR, the findings showed that these factors are promising for
properly selecting and treating patients whowill optimally benefit
from reRT. As for size of the recurred tumor and the total reRT
dose, a phase II study by Cai et al. have attributed their low
local control and clinical response rate to the large portion of
patients with tumors larger than 3 cm and those who received a
low total reRT dose (24). In our study, tumor size and higher reRT
dose were significant factors for IPFR. Lower reRT dose maybe
effective in symptom palliation, but if the tumor progresses, it
will eventually cause symptoms and further re-reRT will be very
challenging. In our subgroup analysis, group 2 (definitive reRT
group) showed the highest IPFR compared to those treated with
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salvage reRT with a surgical component or palliative reRT. This
may be explained by the fact than group 2 showed the smallest
median recurred tumor size of 2.9 cm and highest median reRT
total dose of 53.1 Gyab10. As for severe late toxicity, patients who
did not experience severe late toxicity events showed a higher
number of recurred tumors at the posterior or lateral location.
In our study, the locations of the recurrent rectal tumors were
classified as axial, anterior, posterior, or lateral. Because axial and
anterior tumors are closer to normal organs such as the bowel
or bladder, they are at a higher risk for toxicity from reRT than
posterior or lateral tumors. Also, axial and anterior tumors are
associated with a higher rate of R0 resection, whereas extensive
posterior or lateral tumors involving the sacral promontory, iliac
vessels, or the pelvic wall are contraindications for radical surgery
(25, 26). Thus, location is also an important factor in deciding
reRT for recurrent rectal cancer. Therefore, treating patients with
recurred tumors located posteriorly or laterally and tumor size
<3.3 cm with a total reRT dose of>50 Gyab10 to the GTVmaybe
the most optimal strategy.
To reduce toxicity and increase treatment efficacy for reRT,
more advanced RT techniques should be developed. Recently,
particle therapy such as carbon-ion therapy has gained attention
due to its physical and biologic advantages (27). In Japan, the
Japan Carbon-ion Radiation Oncology Study Group reported a
3-year OS rate of 73% and grade 3 late toxicity rate of 5.4%
in patients with locally recurrent rectal cancer, including both
reRT and non-reRT patients (28). In Germany, the first results
for 19 patients with locally recurrent rectal cancer who received
reRT using carbon-ion therapy were reported. Moreover, there is
an ongoing phase I/II trial evaluating carbon ion radiotherapy
for the treatment of recurrent rectal cancer (PANDORA-01
trial) (29, 30).
There are several limitations to this study due to its
retrospective nature. First is the heterogeneity of tumor and
treatment characteristics at recurrence. Second, there may have
been late toxicity events in the patients lost to follow-up. Also,
the small number of patients could have influenced the results.
However, the number of patients is not too small compared to
that of other previous studies on reRT for recurrent rectal cancer.
Moreover, to the best of our knowledge, this is the first study
to identify and analyze a patient subgroup that could optimally
benefit from reRT.
In conclusion, our findings demonstrate that reRT for patients
with locoregionally recurrent rectal cancer is a reasonable
treatment option, considering the good treatment outcome and
low acute toxicity rates. However, because severe late toxicity
rates were substantially high, patients for reRT should be selected
carefully. To improve the therapeutic ratio, reRT with curative
dose for patients selected properly according to tumor size
and location may be considered an attractive strategy for loco-
regionally recurrent rectal cancer patients.
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Supplementary Figure 3 | Sample radiotherapy plan for a patient who
experienced severe late toxicity related to the organ at risk included in the PTV.
This patient developed a fistulous connection between the posterior wall of the
bladder and the dead space.
Supplementary Figure 4 | Kaplan-Meier estimates of overall survival (A) and
progression-free survival (B) according to the selected patient subgroup or
other patients.
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Supplementary Table 4 | Factors related to severe late toxicity.
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